Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Arch Neurol. Author manuscript; available in PMC 2009 October 18.
Published in final edited form as:
PMCID: PMC2763140

The Expanding Role of Genetics in the Lewy Body Diseases: The Glucocerebrosidase Gene

In this month’s Archives, 2 articles describe the association of mutations in the glucocere-brosidase gene (GBA) with Parkinson disease (PD) and dementia with Lewy bodies (DLB).1,2 These studies add to the growing literature linking mutations in GBA to diseases characterized clinically by parkinsonism and pathologically by the presence of Lewy body–related pathology (LRP) (including classic Lewy bodies and abnormal α-synuclein inclusions and neurites). Historically, the link between GBA and LRP-associated diseases began with case reports noting clinical parkinsonism in Ashkenazi Jewish patients with Gaucher disease (GD).3,4 Subsequent examination of larger samples of patients with GD found a high frequency of parkinsonism and the presence of LRP in some of these patients.5 The next question was whether there was an increased frequency of GBA mutations in PD, particularly in samples that were not Ashkenazi Jewish. Subsequent studies of multiple PD samples did, in fact, find a higher than expected frequency of GBA mutations.610

However, until this point the study samples were either small, often with limited control samples, or only evaluated the most frequently observed GBA mutations (ie, did not sequence the entire gene). Likely owing to these methodological limitations, the reported frequency of GBA mutations in PD samples has been quite variable.

In this month’s Archives, Mitsui et al2 addressed both of these limitations by sequencing all of the coding regions of GBA in an impressively large sample of Japanese patients with PD and controls (n = 534 and 544, respectively). They found that almost 10% of their PD group carried GBA mutations, whereas these variants were rare in the control group (<1%). It was also reassuring to see that they found no difference in the frequency of non-pathogenic GBA variants between the PD and control groups. Given the rather large number of cases of PD with GBA pathogenic variants, they were able to examine clinical characteristics of the parkinsonian symptoms and found an earlier age of onset and frequent positive response to dopaminergic therapy (supporting other recent reports of GBA mutation–associated PD6,11,12).

In the other GBA article in this month’s Archives, Clark et al1 examined the frequency of GBA pathogenic variants in a sample of patients with DLB. Similar to the article by Matsui et al, they sequenced all of the GBA exons. Though the study sample was somewhat smaller (n = 95), this study was notable for the use of pathologically confirmed LRP. They also found a remarkably high frequency of pathologic variants of GBA in their sample. Of particular interest was the absence of an association with the pathological changes of Alzheimer disease. Lewy body pathology is frequently observed in Alzheimer disease, even in familial forms,13,14 but it is not clear if this type of Lewy body disease is pathophysiologically linked to Alzheimer disease or to the more pathologically pure forms of Lewy body disease. These findings would appear to support the former. A caveat in this study was the use of a New York City–area study sample; thus, the relatively high frequency of the N370S variant may have been due to the high representation of Ashkenazi Jewish persons in their sample. One previous study has examined GBA mutations in an even smaller sample of pathologically confirmed DLB (n = 54), but only evaluated those cases for 2 specific GBA mutations rather than sequencing all of the coding regions.7 This likely accounts, in part, for the even lower frequency of GBA mutations found in this latter study.

These are the largest studies of GBA pathologic variants in PD and DLB and not only solidify the GBA–Lewy body disease connection, but suggest strongly that GBA mutations are, to date, the most common genetic risk factor for Lewy body diseases. One firm conclusion from these studies is that there is a need in genetic studies of GBA, and in studies of other susceptibility genes, to perform sequencing of all of the coding regions. As stated by Matsui et al,2 “ … we should emphasize a paradigm shift from the ‘common disease–common variants hypothesis’ to the ‘common disease–multiple rare variants hypothesis’ in our search for disease susceptibility genes in sporadic PD …” This, unfortunately, is not a small task, as the technical difficulties, particularly owing to the presence of a highly homologous GBA pseudogene (GBAP),15 and the workload associated with detailed sequencing of GBA are significant.

The clinical implications of these findings will need to be resolved. Clinical genetic testing and counseling implications will have to be addressed, likely dependent on further research examining the risk for Lewy body disease in patients heterozygous for GBA mutations. This may be difficult given the apparent heterogeneous genotype-phenotype correlations with specific GBA mutations in GD.15 Another important clinical question is whether GD biomarkers16 could assist with the development of biomarkers for PD. There have been some limited attempts up to this point17; however there has been no correlation to GBA genotyping.

Finally, what does this tell us about the pathophysiology of Lewy body disorders such as PD and DLB? A laundry list of potential mechanisms could be and have been hypothesized.18 Is this a gain-of-function mechanism or related to a modest loss of function? The presence of parkinsonism or PD in GD would appear to support the latter. It does appear, however, that we can have confidence that GBA has an important role in the pathophysiology of Lewy body disorders, and that a better understanding of this link should provide new avenues of research and treatment for the Lewy body disorders.


Financial Disclosure: None reported.

Funding/Support: This study was supported in part by Veterans Affairs and grants AG005136 and AG005133 from the National Institute on Aging.


Author Contributions: Study concept and design: Leverenz, Lopez, and DeKosky. Analysis and interpretation of data: Leverenz, Lopez, and DeKosky. Drafting of the manuscript: Leverenz, Lopez, and DeKosky. Critical revision of the manuscript for important intellectual content: Leverenz, Lopez, and DeKosky. Obtained funding: Leverenz, Lopez, and DeKosky.


1. Clark LN, Kartsaklis LA, Gilbert RW, et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol. 2009;66(5):578–583. [PMC free article] [PubMed]
2. Mitsui J, Mizuta I, Toyoda A, et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol. 2009;66(5):571–576. [PubMed]
3. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM. 1996;89(9):691–694. [PubMed]
4. Machaczka M, Rucinska M, Skotnicki AB, Jurczak W. Parkinson’s syndrome preceding clinical manifestation of Gaucher’s disease. Am J Hematol. 1999;61 (3):216–217. [PubMed]
5. Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab. 2003;79(2):104–109. [PubMed]
6. Clark LN, Ross BM, Wang Y, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology. 2007;69(12):1270–1277. [PubMed]
7. Mata IF, Samii A, Schneer SH, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol. 2008;65(3):379–382. [PMC free article] [PubMed]
8. Sato C, Morgan A, Lang AE, et al. Analysis of the glucocerebrosidase gene in Parkinson’s disease. Mov Disord. 2005;20(3):367–370. [PubMed]
9. Wu YR, Chen CM, Chao CY, et al. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry. 2007;78(9):977–979. [PMC free article] [PubMed]
10. Ziegler SG, Eblan MJ, Gutti U, et al. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab. 2007;91(2):195–200. [PMC free article] [PubMed]
11. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008;70 (24):2277–2283. [PubMed]
12. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol. 2008;65(10):1353–1357. [PMC free article] [PubMed]
13. Hamilton RL. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10(3):378–384. [PubMed]
14. Leverenz JB, Fishel MA, Peskind ER, et al. Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol. 2006;63(3):370–376. [PMC free article] [PubMed]
15. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA) Hum Mutat. 2008;29(5):567–583. [PubMed]
16. Cox TM, Aerts JM, Belmatoug N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis. 2008;31(3):319–336. [PubMed]
17. Balducci C, Pierguidi L, Persichetti E, et al. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson’s disease. Mov Disord. 2007;22(10):1481–1484. [PubMed]
18. Hruska KS, Goker-Alpan O, Sidransky E. Gaucher disease and the synucleinopathies. J Biomed Biotechnol. 2006;2006(3):78549. [PMC free article] [PubMed]